Secondary outcome
Dyspnea
ADVERSE EVENTS, SECONDARY, PCT
The secondary outcomes of this trial were radiological and clinical indicators on baseline (day 0–2), 15 (± 2), and 22 (± 2) days: (1) Brixia score for radiographic severity; (2) mMRC Dyspnea scale; (3) oxygenation index; (4) duration of oxygen therapy (days); (5) peripheral oxygen saturation; (6) 6 MW test; (7) PEF; (8) PCT; (9) ESR; and (10) CRP levels. In addition, adverse events (AE) and serious adverse events (SAE) were recorded until day 91 (± 2) since randomization.